Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 151

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 151
---
 specified in the CVR
Agreement.

Support Agreement

Concurrently with the execution
of the Merger Agreement, the Company entered into support agreements, each, a Support Agreement with certain shareholders and of the Company,
or the Supporting Persons, covering approximately 40% of the outstanding Common Shares as of January 31, 2025. Pursuant to the Support
Agreements, each Supporting Person has agreed, among other things, to vote its Common Shares, and any other voting securities such Supporting
Person might hold, in favor of (A) (i) the issuance of Common Shares equal to the required number of Common Shares to serve as the
Merger Consideration, and (ii) an ordinary capital increase under Swiss law, excluding the subscription rights of the existing holders
of Common Shares, for the purpose of making available the required number of Common Shares to serve as the Merger Consideration, and (B)
any proposal to adjourn or postpone the shareholder meeting called to vote upon resolutions (A)(i) and (ii) to a later date if there are
not sufficient votes to approve resolutions (A)(i) and (ii). The Support Agreement will terminate upon the earliest to occur of (a) the
date that the Shareholder Resolutions (as defined in the Support Agreements) are approved, (b) the termination of the Merger Agreement
in accordance with its terms, (c) written notice of termination of the Support Agreement by the Company to the Supporting Person, and
(d) 365 days from the Effective Date (as defined in the Support Agreements).

In 2024, 2023 and 2022
our capital expenditures amounted to $0, $0, and $0, respectively. Our current capital expenditures are primarily for software and office
furniture substantially all in Switzerland, and we expect to finance these expenditures primarily from cash on hand.

B. Business Overview

We are a clinical-stage
biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex CNS
disorders with unmet medical needs. Our lead compound mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2
agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy (lead indication), IH (follow-on
indication) and potentially ADHD (back-up indication). We believe that this unique mechanism of action will also enable Mazindol ER
to provide potential therapeutic benefit